EUVIMEDDescoperă EUVIMED
Übersichtsarbeit

Small Molecule Inhibitors Targeting Cdc2‐Like Kinase 4: Advances, Challenges, and Opportunities

Yu Jiang, Zihua Tang, Minggao Jiang, Jing Wang iD, Yanhai Wang

Chemical Biology & Drug Design · 2025

DOI: 10.1111/cbdd.70087 ↗

At a glance

Übersichtsarbeit in Chemical Biology & Drug Design, 2025. Written by Yu Jiang and 4 co-authors. Institution: West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, China. Major MEDLINE topics: Protein Kinase Inhibitors, Small Molecule Libraries. Cited 5 times so far (Crossref); 57 references.

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

Cdc2‐like kinase 4 (Clk4), a key member of the CMGC kinase family, plays a crucial role in alternative splicing, which profoundly influences various physiological processes, including cellular signaling, proliferation, and survival. Its involvement in these vital functions has positioned Clk4 as an important target for therapeutic intervention in a range of diseases, such as neurodegenerative disorders, viral and parasitic infections, and cancer. This review highlights recent advancements in Clk4 inhibitors, covering both natural, and synthetic compounds. It further examines the core scaffolds and essential functional groups of Clk4 small‐molecule inhibitors, emphasizing the most promising chemical structures. Additionally, the review explores the structure–activity relationships (SARs) and molecular binding modes of existing Clk4 inhibitors, offering insights and strategies for the development of novel Clk4‐targeted drugs. This review highlights recent advancements in small molecule inhibitors targeting Clk4, emphasizing their potential in treating cancers and neurodegenerative diseases. It explores SARs, binding modes, and challenges in developing selective Clk4 inhibitors, offering insights for future therapeutic strategies.

Subjects

MeSH terms (MEDLINE)

Protein Kinase InhibitorsSmall Molecule LibrariesHumansStructure-Activity RelationshipNeoplasmsNeurodegenerative DiseasesCDC2-CDC28 KinasesAnimalsProtein Serine-Threonine KinasesProtein Binding

Author keywords

Clk4SARanticancerkinase inhibitorssmall molecule inhibitors

Substances

Protein Kinase InhibitorsSmall Molecule LibrariesCDC2-CDC28 KinasesProtein Serine-Threonine Kinases

Authors and institutions

  • West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, China.
  • Pediatric Otolaryngology Head and Neck Surgery, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, West China Second University Hospital, Sichuan Univ…
  • Department of Orthodontics, School and Hospital of Stomatology, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.

ORCID profiles: Jing Wang

Cite

APA

Jiang, Y., Tang, Z., Jiang, M., Wang, J., & Wang, Y. (2025). Small Molecule Inhibitors Targeting Cdc2‐Like Kinase 4: Advances, Challenges, and Opportunities. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70087

Vancouver

Jiang Y, Tang Z, Jiang M, Wang J, Wang Y. Small Molecule Inhibitors Targeting Cdc2‐Like Kinase 4: Advances, Challenges, and Opportunities. Chemical Biology & Drug Design. 2025. doi:10.1111/cbdd.70087

BibTeX
@article{Jiang2025,
  author = {Jiang, Yu and Tang, Zihua and Jiang, Minggao and Wang, Jing and Wang, Yanhai},
  title = {Small Molecule Inhibitors Targeting Cdc2‐Like Kinase 4: Advances, Challenges, and Opportunities},
  journal = {Chemical Biology & Drug Design},
  year = {2025},
  doi = {10.1111/cbdd.70087}
}
Start for free →